Sangamo Therapeutics, Inc.’s Free Cash Flow at a glance
Sangamo Therapeutics, Inc. reports free cash flow of -$67.4M for Dec 2024. The prior period recorded -$246.0M (Dec 2023). Year over year the metric moved +$178.6M (+72.6%). The rolling three-period average stands at -$185.7M. Data last refreshed Dec 7, 2025, 2:52 AM.
Latest reading
-$67.4M · Dec 2024
YoY movement
+$178.6M (+72.6%)
Rolling average
-$185.7M
Current Free Cash Flow
-$67.4M
+$178.6M
+72.6%
Rolling average
-$185.7M
Latest Value
-$67.4M
Dec 2024
YoY Change
+$178.6M
Absolute
YoY Change %
+72.6%
Rate of change
3-Period Avg
-$185.7M
Smoothed
Narrative signal
Sangamo Therapeutics, Inc.’s free cash flow stands at -$67.4M for Dec 2024. Year-over-year, the metric shifted by +$178.6M, translating into a +72.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How free cash flow shapes Sangamo Therapeutics, Inc.'s story
As of Dec 2024, Sangamo Therapeutics, Inc. reports free cash flow of -$67.4M. Track free cash flow trends, reinvestment capacity, and balance sheet flexibility using historical cash flow statements.
Why free cash flow matters
Free cash flow underpins dividends, buybacks, debt reduction, and reinvestment. It is a critical input for equity valuations and credit analysis.
Evaluating free cash flow volatility
Consider cash flow stability alongside growth. Large swings can signal heavy capital investment cycles or working capital shifts that may not repeat.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
100%
Operating Margin
-179.9%
Net Profit Margin
-169.4%
Return on Equity
-430.1%
Return on Assets
-96.4%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Sangamo Therapeutics, Inc. (SGMO) FAQs
Answers tailored to Sangamo Therapeutics, Inc.’s free cash flow profile using the latest Financial Modeling Prep data.
What is Sangamo Therapeutics, Inc.'s current free cash flow?
As of Dec 2024, Sangamo Therapeutics, Inc. reports free cash flow of -$67.4M. This reading reflects the latest filings and price data for SGMO.
How is Sangamo Therapeutics, Inc.'s free cash flow trending year over year?
Year-over-year, the figure shifts by +$178.6M (+72.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for SGMO.
Why does free cash flow matter for Sangamo Therapeutics, Inc.?
Free cash flow reflects the cash a company generates after funding operations and capital expenditures. For Sangamo Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Sangamo Therapeutics, Inc.'s free cash flow above its recent average?
Sangamo Therapeutics, Inc.'s rolling three-period average sits at -$185.7M. Comparing the latest reading of -$67.4M to that baseline highlights whether momentum is building or fading for SGMO.
How frequently is Sangamo Therapeutics, Inc.'s free cash flow refreshed?
Data for SGMO was last refreshed on Dec 7, 2025, 2:52 AM and updates automatically every 24 hours, keeping your valuation inputs current.